<DOC>
	<DOCNO>NCT02472535</DOCNO>
	<brief_summary>A 12-week , open-label , dose-escalating , phase 2 study evaluate effect MBX-8025 patient Homozygous Familial Hypercholesterolemia ( HoFH ) .</brief_summary>
	<brief_title>Study Evaluate Effects MBX-8025 Patients With HoFH</brief_title>
	<detailed_description>Open-label , single arm , non-controlled , dose ascending ( 50 mg/day , 100 mg/day 200 mg/day ) three consecutive dose escalation period . After sign informed consent subject enter screen period run-in stabilization period . At end run-in period patient enter treatment phase . MBX-8025 ascending dos ( 50 mg , 100 mg , 200 mg ) give within three consecutive 4 week period , total 12 week . At end treatment , subject enter follow-up period .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>1 . Must give write informed consent ( sign date ) authorization require local law able comply study requirement . 2 . Male female HoFH confirm genotype ( two mutant allele LDLReceptor ( LDLR ) gene locus double heterozygote LDLR/ApoB ) . 3 . 18 year age old . 4 . Existing lipid lower therapy ( statin , cholesterol absorption inhibitor , bile acid sequestrants , nicotinic acid combination , lowdensity lipoprotein ( LDL ) LDLC apheresis ) stable regimen least four week screen visit . 5 . Stable lipid lower diet compatible Step I diet American Heart Association ( AHA ) . 6 . Fasting LDLC ≥ 4.8 mmol/L ( ≥ 185.6 mg/dL ) screening . 7 . For female male reproductive potential , use least one barrier contraceptive second effective birth control method study least two week last dose . 1 . Treatment lomitapide mipomersen within two month screen . 2 . Heart Failure ( HF ) New York Heart Association ( NYHA ) class III class IV Left ventricular ejection fraction ( LVEF ) less 30 % . 3 . Uncontrolled cardiac arrhythmia past three month screen . 4 . Myocardial infarction , unstable angina , percutaneous coronary intervention , coronary artery bypass graft stroke past three month screen . 5 . Planned cardiac surgery , plan revascularization , next four month . 6 . Uncontrolled hypertension . 7 . Aspartate transaminase ( AST ) Alanine transaminase ( ALT ) ≥ 3 time Upper Limit Normal ( ULN ) . 8 . Unexplained creatine kinase ( CK ) ≥ 5 time upper limit normal ( ULN ) . 9 . For female , pregnancy breastfeeding . 10 . Any condition ( ) would compromise safety patient compromise quality clinical study judge Investigator and/or Medical Monitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>HoFH</keyword>
</DOC>